Adagio(IVVD) - 2024 Q2 - Quarterly Results

Exhibit 99.1 INVIVYD REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS • PEMGARDA™ launched commercially in Q2 2024 with $2.3 million of net product revenue • Notable acceleration of commercial results in early Q3 2024, with the anticipated peak fall/winter respiratory virus season approaching • New commercial leadership with Chief Commercial Of icer, Tim Lee, an experienced biopharmaceutical leader with demonstrated commercial success • Achieved Medicare and Medicaid coverage, ra ...